Everything in biotech comes down to perception. CU6, which has...

Everything in biotech comes down to perception. CU6, which has been going far long than RAC (even if it has been listed for less), spent the first couple of years post IPO doing absolutely nothing SP wise. It was so bad that by mid 2022 it got down to cash backing - an EV of $0. Nothing happened for the next 12 months after that then all of a sudden it took off like a rocket as suddenly the hope of a quick buy out took hold in the market.

I can’t tell you when or if something similar will happen with RAC, but there is no reason that sentiment can’t suddenly change just like it did with CU6.